Delivery of gene products via mesangial cells
AssigneeThe Jikei University School of Medicine
InventorMasanori Kitamura
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe Jikei University School of Medicine
InventorMasanori Kitamura
Estimating the term…
Disclosed are methods that achieve i) site-directed delivery, ii) in situ amplification, and iii) sustained expression of an exogenous gene product within renal glomeruli. An exogenous gene, E. coli .beta.-galactosidase, was introduced into cultured rat mesangial cells using a replication-defective retrovirus, and stable infectants were administered to a rat kidney via the renal artery. In the injected kidney, the engineered, cultured mesangial cells populated 40% of glomeruli site-specifically. The gene product was detected throughout a 14-week period of observation. In an alternative method, engineered, cultured mesangial cells were injected into a kidney subjected to an antibody that induces mesangiolysis followed by mesangial regeneration. Under these conditions, expression of .beta.-galactosidase was dramatically amplified in situ, and high level expression continued for at least 8 weeks.
A method of introducing cultured mesangial cells into at least one of the two kidneys of a mammal, each said kidney having in situ mesangial cells in glomeruli and supplied by a renal artery, comprising the steps of:
Dependencies are inferred from the claim text.